Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions
- Sponsors CSL Behring
- 17 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Mar 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
- 17 Feb 2017 This trial was completed in Czech Republic, according to European Clinical Trials Database.